BCG Vaccine Triggers SARS-CoV-2 Specific T-cell Response

Several studies have shown that individuals who have recovered from COVID-19 have SARS-CoV-2 specific T-cell memory and T-cell dysfunction. Hence T-cells play a pivotal role in mounting a robust immune response against COVID-19. Cross-reactive T-cells between human coronaviruses and SARS-CoV-2 have been previously identified. This suggests the possibility of T-cell cross-protection in COVID-19. Many epidemiological studies suggest that the Bacillus Calmette-Guérin (BCG) vaccine could offer protection against COVID-19. Currently, there are more than 15 clinical trials in progress to determine if BCG vaccination can help reduce or prevent the severity of COVID-19 disease.

Researchers from the Monash University and Monash Medical Centre, Australia, investigated whether peptide sensitization using BCG can produce cross-reactive T-cells against COVID-19. The researchers identified 8 BCG-derived peptides in silico. They used in vitro co-culture system and showed that human CD8+ and CD4+ T-cells primed with a BCG-derived peptide developed high reactivity to its corresponding SARS-CoV-2 derived peptide. All 20 individuals primed with BCG-derived peptides developed improved T-cell reactivity to 7 of 8 SARS-CoV-2 derived peptides. The IFN-g and TNF response was mixed. It was also observed that CD8+ T-cells primed with BCG-derived peptides showed an enhanced perforin expression. 

To know more about origin, virology of COVID-19, Click here

To know more about emerging themes in COVID-19, Click here

To know more about how WhiteCoats can help you in your professional advancement, visit www.whitecoats.com

Want to set up an online consultation for your practice, Click here

Ref link: https://www.medrxiv.org/content/10.1101/2020.11.21.20236018v1

#Featured